Skin allografts-host cutaneous veiled cells initiate rejection reaction by indirect pathway of allorecognition.

[1]  R. Jain,et al.  Angiogenesis in the huPBL-SCID model of human transplant rejection. , 1999, Transplantation.

[2]  A. Valujskikh,et al.  Contributions of direct and indirect T cell alloreactivity during allograft rejection in mice. , 1999, Journal of immunology.

[3]  J. Pober,et al.  Dermal microvascular injury in the human peripheral blood lymphocyte reconstituted-severe combined immunodeficient (HuPBL-SCID) mouse/skin allograft model is T cell mediated and inhibited by a combination of cyclosporine and rapamycin. , 1998, The American journal of pathology.

[4]  J. Arrighi,et al.  Transformed and nontransformed human T lymphocytes migrate to skin in a chimeric human skin/SCID mouse model. , 1997, The Journal of investigative dermatology.

[5]  H. Gałkowska,et al.  Reactivity of antibodies directed against human antigens with surface markers on canine leukocytes. , 1996, Veterinary immunology and immunopathology.

[6]  M. D. de Roos,et al.  SCID mouse as a model for transplantation studies. , 1996, The Journal of surgical research.

[7]  H. Auchincloss,et al.  Effector cells must recognize antigens expressed in the graft to cause efficient skin graft rejection in SCID mice. , 1995, Transplantation.

[8]  L. Grimaldi,et al.  The fate of human peripheral blood lymphocytes after transplantation into SCID mice , 1993, European journal of immunology.

[9]  E. Sercarz,et al.  Donor major histocompatibility complex (MHC) peptides are presented by recipient MHC molecules during graft rejection , 1992, The Journal of experimental medicine.

[10]  R. Steinman,et al.  Granulocyte/macrophage colony-stimulating factor is essential for the viability and function of cultured murine epidermal Langerhans cells , 1987, The Journal of experimental medicine.